ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,686,961 | -56.7% | 1,856,380 | -50.2% | 0.00% | -55.6% |
| Q2 2023 | $89,285,121 | +21.2% | 3,727,980 | -4.8% | 0.01% | +12.5% |
| Q1 2023 | $73,674,730 | +68.6% | 3,914,704 | +42.6% | 0.01% | +60.0% |
| Q4 2022 | $43,696,228 | -13.0% | 2,744,738 | -10.6% | 0.01% | -28.6% |
| Q3 2022 | $50,244,000 | +14.3% | 3,071,113 | -1.6% | 0.01% | +16.7% |
| Q2 2022 | $43,961,000 | +93.0% | 3,120,072 | +231.8% | 0.01% | +100.0% |
| Q1 2022 | $22,777,000 | +47.3% | 940,382 | +41.9% | 0.00% | +50.0% |
| Q4 2021 | $15,466,000 | +13.4% | 662,659 | -19.3% | 0.00% | 0.0% |
| Q3 2021 | $13,640,000 | -33.1% | 821,243 | -1.7% | 0.00% | -33.3% |
| Q2 2021 | $20,381,000 | +22.8% | 835,652 | +30.0% | 0.00% | +50.0% |
| Q1 2021 | $16,591,000 | -39.1% | 643,050 | +26.2% | 0.00% | -50.0% |
| Q4 2020 | $27,237,000 | +36.0% | 509,483 | +4.9% | 0.00% | 0.0% |
| Q3 2020 | $20,032,000 | +137.6% | 485,639 | +179.2% | 0.00% | +100.0% |
| Q2 2020 | $8,430,000 | +10.0% | 173,932 | -4.1% | 0.00% | 0.0% |
| Q1 2020 | $7,665,000 | -66.9% | 181,444 | -66.5% | 0.00% | -60.0% |
| Q4 2019 | $23,170,000 | +110.5% | 541,647 | +77.1% | 0.01% | +66.7% |
| Q3 2019 | $11,009,000 | +191.0% | 305,881 | +116.1% | 0.00% | +200.0% |
| Q2 2019 | $3,783,000 | -13.5% | 141,521 | -13.1% | 0.00% | 0.0% |
| Q1 2019 | $4,372,000 | +0.7% | 162,835 | -39.4% | 0.00% | 0.0% |
| Q4 2018 | $4,342,000 | -19.6% | 268,541 | +3.2% | 0.00% | 0.0% |
| Q3 2018 | $5,403,000 | -62.3% | 260,255 | -72.2% | 0.00% | -75.0% |
| Q2 2018 | $14,319,000 | +39.3% | 937,707 | +105.0% | 0.00% | +33.3% |
| Q1 2018 | $10,279,000 | -62.0% | 457,480 | -49.1% | 0.00% | -57.1% |
| Q4 2017 | $27,060,000 | +97.7% | 898,714 | +147.3% | 0.01% | +75.0% |
| Q3 2017 | $13,689,000 | +126.2% | 363,392 | +67.5% | 0.00% | +100.0% |
| Q2 2017 | $6,052,000 | -53.5% | 216,959 | -42.7% | 0.00% | 0.0% |
| Q1 2017 | $13,012,000 | +17.5% | 378,494 | -1.4% | 0.00% | 0.0% |
| Q4 2016 | $11,074,000 | +59.9% | 383,968 | +76.4% | 0.00% | 0.0% |
| Q3 2016 | $6,925,000 | +28.7% | 217,680 | +31.3% | 0.00% | 0.0% |
| Q2 2016 | $5,381,000 | -24.3% | 165,740 | -34.8% | 0.00% | -33.3% |
| Q1 2016 | $7,110,000 | -37.9% | 254,298 | -20.8% | 0.00% | -25.0% |
| Q4 2015 | $11,449,000 | +17.8% | 321,183 | +9.3% | 0.00% | 0.0% |
| Q3 2015 | $9,719,000 | -12.1% | 293,923 | +11.3% | 0.00% | 0.0% |
| Q2 2015 | $11,058,000 | +16.9% | 264,057 | -9.0% | 0.00% | +33.3% |
| Q1 2015 | $9,462,000 | -41.8% | 290,293 | -43.3% | 0.00% | -50.0% |
| Q4 2014 | $16,266,000 | +500.2% | 512,335 | +368.2% | 0.01% | +500.0% |
| Q3 2014 | $2,710,000 | +52.0% | 109,421 | +38.7% | 0.00% | 0.0% |
| Q2 2014 | $1,783,000 | -53.6% | 78,890 | -50.0% | 0.00% | -50.0% |
| Q1 2014 | $3,842,000 | +59.3% | 157,923 | +63.6% | 0.00% | +100.0% |
| Q4 2013 | $2,412,000 | -48.1% | 96,528 | -43.0% | 0.00% | -50.0% |
| Q3 2013 | $4,651,000 | +179.3% | 169,306 | +84.6% | 0.00% | +100.0% |
| Q2 2013 | $1,665,000 | – | 91,731 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |